Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2V617F mutation as a marker of a latent myeloproliferative disorder in a patient with Budd-Chiari syndrome and factor V Leiden mutation.

Thrombosis and haemostasis - 1 Sept 2007

Plumé Gema, Vayá Amparo, Ferrando Fernando, Mira Yolanda, Orbis Francisco

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Budd-Chiari Syndrome
Share to Factor V
Share to Fatal Outcome
Share to Genetic Predisposition to Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Myeloproliferative Disorders

Share to Pedigree

Share to Risk Factors

Source

Identifiers

PMID: 17849060

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2V617F mutation as a marker of a latent myeloproliferative disorder in a patient with Budd-Chiari syndrome and factor V Leiden mutation.PMID 17849060Read ↗

JAK2V617F and prothrombin G20210A gene mutations in a patient with Budd-Chiari syndrome and essential thrombocythemia.Semantic proximity Read ↗

Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.Semantic proximity Read ↗

The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis.Semantic proximity Read ↗

Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.Semantic proximity Read ↗

[Pathogenetic role of JAK2 gene mutation in chronic myeloproliferative disorders].Semantic proximity Read ↗

JAK2V617F mutation in a 9-year-old girl with polycythemia vera and Budd-Chiari syndrome: a case report.Semantic proximity Read ↗

[A recurrent mutation of the JAK2 gene in chronic myeloproliferative disorders].Semantic proximity Read ↗

[JAK2 gene mutation in chronic myeloproliferative disorders].Semantic proximity Read ↗

Budd-Chiari syndrome with underlying homozygous factor V Leiden and heterozygous methylenetetrahydrofolate reductase mutations.Semantic proximity Read ↗

Existence of JAK2 mutation 19 years prior to the development of overt polycythemia vera.Semantic proximity Read ↗

JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia.Semantic proximity Read ↗

Screening of V617F mutation in JAK2 gene with acute myeloid leukemia in the Saudi population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.